(Total Views: 518)
Posted On: 05/29/2020 8:43:54 AM
Post# of 72447
I own quite a bit but I don't see how you're getting anywhere near that number with what we have...
B-ABSSSI: we couldn't justify $30 million for phase 3 and haven't been able to get a decent enough partnership for it that we would resort to 48 million shares to raise $2 million last quarter. We know that we can piece out Brilacidin by indication and delivery method (per the B-UP deal). I think we have come to realize the economics aren't there to make a fortune on an antibiotic any more. Surely any reasonable deal on B-ABSSSI would have been preferable to the dilution we have faced over the past two years.
B-UP: Formed a partnership with a 2-6% royalty and $18M in sales milestones for $450K upfront and $6M in regulatory milestones. We likely won't see even the first $1M of the regulatory payments until we learn the fate of B-UC. Here we get a glimpse of our negotiating prowess on an indication supposedly worth $100M/year. This doesn't bode well for future negotiations.
B-UC: We need to run a phase 2 to see how well it works in pill form. Biggest potential in the pipe but it needs a phase 2...preferably a sizable one so we don't get shafted like with B-UP.
B-OM: We're engaged in finding a partner. We're not in any stronger cash position than we were for the B-UP negotiations. We have Dr. Menon banging on the door for his money. I'm not expecting great terms on this deal.
B-COVID: Looks like it's working well in vitro. Needs testing in humans.
We're a broke company with no leverage that just can't seem to seal a decent partnership or make it into a phase 3 trial. I'm invested hoping for $1.92 and dreaming of $19.20. $192+....just don't see it without an angel's blessing.
Go IPIX!
B-ABSSSI: we couldn't justify $30 million for phase 3 and haven't been able to get a decent enough partnership for it that we would resort to 48 million shares to raise $2 million last quarter. We know that we can piece out Brilacidin by indication and delivery method (per the B-UP deal). I think we have come to realize the economics aren't there to make a fortune on an antibiotic any more. Surely any reasonable deal on B-ABSSSI would have been preferable to the dilution we have faced over the past two years.
B-UP: Formed a partnership with a 2-6% royalty and $18M in sales milestones for $450K upfront and $6M in regulatory milestones. We likely won't see even the first $1M of the regulatory payments until we learn the fate of B-UC. Here we get a glimpse of our negotiating prowess on an indication supposedly worth $100M/year. This doesn't bode well for future negotiations.
B-UC: We need to run a phase 2 to see how well it works in pill form. Biggest potential in the pipe but it needs a phase 2...preferably a sizable one so we don't get shafted like with B-UP.
B-OM: We're engaged in finding a partner. We're not in any stronger cash position than we were for the B-UP negotiations. We have Dr. Menon banging on the door for his money. I'm not expecting great terms on this deal.
B-COVID: Looks like it's working well in vitro. Needs testing in humans.
We're a broke company with no leverage that just can't seem to seal a decent partnership or make it into a phase 3 trial. I'm invested hoping for $1.92 and dreaming of $19.20. $192+....just don't see it without an angel's blessing.
Go IPIX!
(4)
(1)
